SAHPRA: South Africa Lacks Clear Medicine Shortage Reporting Requirements

• South Africa's legal framework currently lacks a clear definition for "medicines shortage" and does not mandate proactive reporting to SAHPRA.
• In contrast, the US and EU have robust regulations requiring manufacturers to report shortages, supply disruptions, and product discontinuations to their respective regulators.
• These international systems include requirements for advanced warning and public databases detailing current and resolved shortages.
• SAHPRA's online register notes cancelled products but does not provide cancellation dates or reasons for discontinuation.
• Section 19(2) of the Medicines and Related Substances Act allows SAHPRA to request information, but it does not establish an ongoing reporting obligation for supply chain issues.

The absence of explicit SAHPRA medicine shortage reporting requirements presents a unique landscape for pharmaceutical compliance South Africa.

Globally, the persistent issue of medicine and vaccine shortages has emerged as a significant public health concern, extending far beyond the scope of pandemics or public health emergencies. Many high-income nations have implemented robust legal and regulatory frameworks to proactively manage and mitigate these supply disruptions. However, within South Africa, the legal landscape currently lacks a precise definition for what constitutes a "medicines shortage," a fundamental element for effective regulation.

This contrasts sharply with international efforts, such as the draft United Nations High-Level Declaration on Pandemic Prevention, Preparedness and Response, where a political declaration was considered on September 25, 2026, with leaders renewing commitments to global action, underscoring deep concerns regarding inequities in access to health products and systemic shortcomings in global health emergency responses. The absence of a clear legal definition in the country sets a foundational challenge for any comprehensive strategy to address these critical supply chain vulnerabilities.

In stark contrast to the situation in South Africa, leading international jurisdictions have established clear and enforceable `SAHPRA medicine shortage reporting requirements` for pharmaceutical manufacturers. In the United States, for instance, the Federal Food, Drug, and Cosmetic Act explicitly defines a medicine shortage as a period when demand or projected demand outstrips supply. Since 2012, marketing authorization holders in the US have been legally mandated to report shortages to their national medicines regulator. These obligations were further strengthened during the COVID-19 pandemic, now requiring manufacturers to disclose any manufacturing process interruptions likely to cause a significant supply disruption, along with the underlying reasons. Furthermore, advanced notice and justification are required for permanent production discontinuations. The US Food and Drug Administration (FDA) maintains a publicly accessible database detailing current and resolved shortages and discontinuations, complemented by a separate resource from the American Society of Health-System Pharmacists.

Similarly, the European Medicines Agency (EMA) and its national counterparts recognize medicine shortages as a critical public health issue. Since early 2025, manufacturers operating within the European Union have been required to report shortages to the European Shortages Monitoring Platform. Both the EMA and individual national agencies maintain accessible databases for current and resolved shortages, mirroring the transparency efforts seen in the US. Australia's Therapeutic Goods Administration (TGA) also provides a comparable public resource, demonstrating a widespread international commitment to proactive monitoring and public disclosure of pharmaceutical supply chain issues.

Despite the global trend towards enhanced transparency and proactive reporting, the `South African Health Products Regulatory Authority` (SAHPRA) currently operates without equivalent `SAHPRA medicine shortage reporting requirements`. This means there is no legal obligation for manufacturers or distributors to proactively inform the regulator about impending medicine shortages or product discontinuations. Consequently, SAHPRA does not make any such data publicly accessible, creating a significant information vacuum for healthcare providers and patients alike.

While SAHPRA's online register lists products with "Cancelled" status, it critically omits the date of cancellation and, more importantly, the reasons behind a product's discontinuation. This regulatory gap means that health professionals and patients often discover product discontinuations only after the fact, leaving the regulator without advanced warning or insight into the decisions driving these withdrawals. There is also no comprehensive accounting of the total number of medicines that have been removed from the `South Africa drug supply chain regulation`. Although Section 19(2) of the `Medicines and Related Substances Act` empowers SAHPRA to request information from manufacturers, sellers, or prescribers, this provision is designed for specific, time-bound inquiries rather than establishing an ongoing, permanent reporting process for supply chain disruptions or `medicine discontinuation reporting South Africa`.

The absence of explicit `SAHPRA medicine shortage reporting requirements` presents a unique landscape for `pharmaceutical compliance South Africa`. Unlike their counterparts in the US or EU, manufacturers and distributors operating within the country are not legally compelled to proactively disclose potential supply disruptions or product withdrawals to the regulator. This regulatory environment means that while SAHPRA can reactively request information under the `Medicines and Related Substances Act`, it lacks the systemic foresight provided by mandatory, ongoing reporting mechanisms.

This situation has significant implications for the stability and transparency of the `South Africa drug supply chain regulation`. Without a clear legal framework for `medicine discontinuation reporting South Africa`, the ability to anticipate and mitigate the impact of shortages on patient care is severely hampered. The current state underscores a critical area for potential future regulatory development, aligning South Africa more closely with international best practices aimed at safeguarding public access to essential health products.

Pharmaceutical manufacturers and distributors in South Africa should note the current absence of a clear legal obligation to proactively report medicine shortages or product discontinuations to SAHPRA, contrasting with stricter regimes in the US and EU. This informs compliance strategies regarding supply chain transparency and potential future regulatory developments.

Source: Original reporting via Spotlight